Related Experiment Video
Updated: Nov 15, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Imbalance Between Soluble and Membrane-Bound CD100 Regulates Monocytes Activity in Hepatitis B Virus-Associated
Dong-Na Zhang1, Ye Liu2, Xue Li1
1Department of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Insights
Hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) shows an imbalance in CD100, a key immune protein. This imbalance inactivates monocytes, potentially aiding patient survival.
Area of Science:
- Immunology
- Hepatology
- Virology
Background:
- CD100 is an immune semaphorin involved in infectious diseases.
- Its role in hepatitis B virus (HBV)-associated acute-on-chronic liver failure (ACLF) and innate immunity regulation is unknown.
Purpose of the Study:
- To investigate CD100 levels in HBV-ACLF patients.
- To explore the modulatory function of CD100 on CD14+ monocytes in HBV-ACLF.
Main Methods:
- Analyzed plasma-soluble CD100 (sCD100) and membrane-bound CD100 (mCD100) on CD14+ monocytes.
- Assessed CD14+ monocyte cytotoxicity and T cell activation via co-culture systems with CD100 stimulation.
Main Results:
- HBV-ACLF patients exhibited lower plasma sCD100 and higher mCD100 on CD14+ monocytes compared to controls.
- CD14+ monocytes from HBV-ACLF patients showed reduced cytotoxicity and lower secretion of IFN-γ, TNF-α, and granzyme B.
- Recombinant sCD100 enhanced monocyte cytotoxicity and T cell activation (CD4+ and CD8+) in HBV-ACLF patients.
Conclusions:
- Severe inflammation in HBV-ACLF induces an sCD100/mCD100 imbalance.
- This imbalance may lead to inactivated CD14+ monocyte responses, potentially contributing to patient survival.
Abstract:
CD100 is an important immune semaphorin that is a secreted and membrane bound protein involved in infectious diseases. However, CD100 expression profile and the regulation to innate immune system in hepatitis B virus (HBV)-associated acute-on-chronic liver failure (ACLF) was not previously reported. The aim of this study was to investigate CD100 level and modulatory function of CD100 to CD14+ monocytes in HBV-ACLF patients. Plasma-soluble CD100 (sCD100) level and membrane-bound CD100 (mCD100) expression on peripheral CD14+ monocytes was analyzed in HBV-ACLF patients. CD14+ monocytes-induced cytotoxicity and CD14+ monocytes-mediated T cell activation in response to CD100 stimulation was also assessed in direct and indirect contact coculture culture systems. HBV-ACLF patients had lower plasma sCD100 and higher mCD100 level on CD14+ monocytes compared with asymptomatic HBV carriers, chronic hepatitis B patients, and controls. CD14+ monocytes from HBV-ACLF patients induced limited target Huh7.5 cell death and secreted less interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and granzyme B in both direct and indirect contact coculture systems compared with controls. Recombinant sCD100 not only enhanced CD14+ monocytes-mediated Huh7.5 cell death and granzyme B secretion, but it also elevated CD14+ monocytes-induced IFN-γ/interleukin-17 production by CD4+ T cells as well as IFN-γ/TNF-α secretion by CD8+ T cells in HBV-ACLF patients. The current data indicated that severe inflammation induced sCD100/mCD100 imbalance to inactivate CD14+ monocytes response, which might be beneficial for the survival of HBV-ACLF patients.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

